Q2 earnings
Although the company's rapid growth has been fueled by COVID-19, new contracts and state-by-state trends have CEO Jason Gorevic confident that telehealth adoption is here to stay.
The company laid off more than half of its staff since the beginning of 2019.
Also: uBiome's FBI investigation; Better Therapeutics' pivotal trial plans.